A photo of Rebecca Marsh.

Rebecca A. Marsh, MD


  • Clinical Director, Primary Immune Deficiency Program
  • Co-Director, Diagnostic Immunology Laboratories
  • Clinical Director, HLH Center of Excellence
  • Professor, UC Department of Pediatrics
Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

About

Biography

I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.

As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.

Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.

We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.

Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).

In my free time, I like to play the piano, bake and spend time with my family.

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Histiocytic disorders. McClain, KL; Bigenwald, C; Collin, M; Haroche, J; Marsh, RA; Merad, M; Picarsic, J; Ribeiro, KB; Allen, CE. . 2021.

A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. Arnold, DE; Emoto, C; Fukuda, T; Dong, M; Vinks, AA; Lane, A; McIntosh, K; Neumeier, L; Lankester, AC; Achini, F; et al. Bone Marrow Transplantation. 2021; 56:3029-3031.

Histiocytic disorders. McClain, KL; Bigenwald, C; Collin, M; Haroche, J; Marsh, RA; Merad, M; Picarsic, J; Ribeiro, KB; Allen, CE. Nature Reviews Disease Primers. 2021; 7.

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI). Geerlinks, AV; Scull, B; Krupski, C; Fleischmann, R; Pulsipher, MA; Eapen, M; Connelly, JA; Bollard, CM; Pai, S; Duncan, CN; et al. Blood. 2021; 138:748-748.

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD. Arnold, DE; Nofal, R; Wakefield, C; Lehmberg, K; Wustrau, K; Albert, MH; Morris, EC; Heimall, JR; Bunin, NJ; Kumar, A; et al. Journal of Clinical Immunology. 2021.

Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Khandelwal, P; Teusink-Cross, A; Kumar, AR; Bleesing, JJ; Mehta, PA; Jordan, MB; Chandra, S; Davies, SM; Marsh, RA. British Journal of Haematology. 2021; 194:e84-e89.

A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. Knight, V; Heimall, JR; Chong, H; Nandiwada, SL; Chen, K; Lawrence, MG; Sadighi Akha, AA; Kumánovics, A; Jyonouchi, S; Ngo, SY; et al. Journal of Allergy and Clinical Immunology: In Practice. 2021; 9:3293-3307.e6.

Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. Marsh, RA; Hebert, K; Kim, S; Dvorak, CC; Aquino, VM; Baker, KS; Chellapandian, D; Dávila Saldaña, B; Duncan, CN; Eckrich, MJ; et al. Journal of Allergy and Clinical Immunology. 2021.

α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease. Ibrahimova, A; Davies, SM; Lane, A; Jordan, MB; Lake, K; Litts, B; Chaturvedi, V; Owsley, E; Myers, KC; Nelson, AS; et al. Pediatric Blood and Cancer. 2021; 68.

Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2021.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey